Off-label use of ceftaroline fosamil: A systematic review

•Review of studies on ceftaroline fosamil, a fifth-generation cephalosporin with anti-MRSA activity.•Prescribed off-label in bacteremia, endocarditis, osteoarticular infections, hospital-acquired pneumonia, meningitis.•77% clinical success with off-label ceftaroline and few (9%) adverse events (AEs) reported but not all studies reported AEs.•Studies used different doses/dosing intervals because of renal adjustment and off-label use of higher doses.•Quality of included studies is low because of the retrospective nature of studies, case series and small sample sizes.•More evidence of ceftaroline efficacy and safety required from randomized controlled trials and PK/PD studies.